Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,585 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects.
Li JJ, Liu HH, Wu NQ, Yeo KK, Tan K, Ako J, Krittayaphong R, Tan RS, Aylward PE, Baek SH, Dalal J, Fong AYY, Li YH, O'Brien RC, Lim TSE, Koh SYN, Scherer DJ, Tada H, Kang V, Butters J, Nicholls SJ. Li JJ, et al. Among authors: baek sh. Expert Opin Drug Metab Toxicol. 2020 Sep;16(9):837-851. doi: 10.1080/17425255.2020.1802426. Epub 2020 Aug 11. Expert Opin Drug Metab Toxicol. 2020. PMID: 32729743 Review.
Tackling cardiometabolic risk in the Asia Pacific region.
Li JJ, Yeo KK, Tan K, Ako J, Krittayaphong R, Tan RS, Aylward PE, Lam CP, Baek SH, Dalal J, Fong A, Li YH, O'Brien RC, Koh SYN, Scherer DJ, Tada H, Kang V, Butters J, Nicholls SJ. Li JJ, et al. Among authors: baek sh. Am J Prev Cardiol. 2020 Nov 8;4:100096. doi: 10.1016/j.ajpc.2020.100096. eCollection 2020 Dec. Am J Prev Cardiol. 2020. PMID: 34327472 Free PMC article. Review.
A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mg.
Lee CW, Baek SH, Hong TJ, Choi YJ, Kim YJ, Ahn TH, Ihm SH, Bae JH, Hong SJ, Kim DI, Ahn YK, Hur SH, Park DG, Choi DJ, Lee SU, Kim BS, Ryu KH, Jang YS, Lee SH, Seung KB, Kim HS. Lee CW, et al. Among authors: baek sh. Cardiovasc Drugs Ther. 2010 Apr;24(2):181-8. doi: 10.1007/s10557-010-6225-0. Cardiovasc Drugs Ther. 2010. PMID: 20383571 Clinical Trial.
Correlations between the level of high-sensitivity C-reactive protein and cardiovascular risk factors in Korean adults with cardiovascular disease or diabetes mellitus: the CALLISTO study.
Seo SM, Baek SH, Jeon HK, Kang SM, Kim DS, Kim WS, Kim HS, Rha SW, Park JS, Seong IW, Ahn YK, Yoon JH, Cha TJ. Seo SM, et al. Among authors: baek sh. J Atheroscler Thromb. 2013;20(7):616-22. doi: 10.5551/jat.16089. Epub 2013 May 16. J Atheroscler Thromb. 2013. PMID: 23676341 Free article.
Efficacy and safety of fixed-dose combination therapy with olmesartan medoxomil and rosuvastatin in Korean patients with mild to moderate hypertension and dyslipidemia: an 8-week, multicenter, randomized, double-blind, factorial-design study (OLSTA-D RCT: OLmesartan rosuvaSTAtin from Daewoong).
Park JS, Shin JH, Hong TJ, Seo HS, Shim WJ, Baek SH, Jeong JO, Ahn Y, Kang WC, Kim YH, Kim SH, Hyon MS, Choi DH, Nam CW, Park TH, Lee SC, Kim HS. Park JS, et al. Among authors: baek sh. Drug Des Devel Ther. 2016 Aug 16;10:2599-609. doi: 10.2147/DDDT.S112873. eCollection 2016. Drug Des Devel Ther. 2016. PMID: 27574399 Free PMC article. Clinical Trial.
Efficacy and Safety of Fixed-dose Combination Therapy With Telmisartan and Rosuvastatin in Korean Patients With Hypertension and Dyslipidemia: TELSTA-YU (TELmisartan-rosuvaSTAtin from YUhan), a Multicenter, Randomized, 4-arm, Double-blind, Placebo-controlled, Phase III Study.
Oh GC, Han JK, Han KH, Hyon MS, Doh JH, Kim MH, Jeong JO, Bae JH, Kim SH, Yoo BS, Baek SH, Rhee MY, Ihm SH, Sung JH, Choi YJ, Kim SJ, Hong KS, Lee BK, Cho J, Shin ES, Rhew JY, Kim H, Kim HS. Oh GC, et al. Among authors: baek sh. Clin Ther. 2018 May;40(5):676-691.e1. doi: 10.1016/j.clinthera.2018.03.010. Epub 2018 Apr 17. Clin Ther. 2018. PMID: 29673890 Clinical Trial.
Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority trial.
Hong SJ, Ahn TH, Baek SH, Cho WH, Jeon HK, Kwan J, Yoon MH, Lee KJ, Lim DS. Hong SJ, et al. Among authors: baek sh. Clin Ther. 2006 Apr;28(4):537-51. doi: 10.1016/j.clinthera.2006.04.008. Clin Ther. 2006. PMID: 16750465 Clinical Trial.
1,585 results